Central lymph node dissection as a secondary procedure for papillary thyroid cancer: Is there added morbidity?

Background Routine central lymph node dissection (CLND) for papillary thyroid cancer (PTC) at the time of initial thyroidectomy has been advocated with a demonstrated decrease in post-ablation serum thyroglobulin compared to total thyroidectomy alone. Patients now present with central compartment me...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Surgery 2009-05, Vol.145 (5), p.514-518
Hauptverfasser: Alvarado, Raul, MD, Sywak, Mark S., MBBS, FRACS, Delbridge, Leigh, MD, FACS, Sidhu, Stan B., PhD, FRACS
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 518
container_issue 5
container_start_page 514
container_title Surgery
container_volume 145
creator Alvarado, Raul, MD
Sywak, Mark S., MBBS, FRACS
Delbridge, Leigh, MD, FACS
Sidhu, Stan B., PhD, FRACS
description Background Routine central lymph node dissection (CLND) for papillary thyroid cancer (PTC) at the time of initial thyroidectomy has been advocated with a demonstrated decrease in post-ablation serum thyroglobulin compared to total thyroidectomy alone. Patients now present with central compartment metastatic disease after initial thyroid cancer surgery, or with a diagnosis of PTC after diagnostic lobectomy requiring completion thyroidectomy, and an undissected central compartment. Our aim was to compare the clinical outcomes in patients with PTC who underwent CLND as a secondary event with those having initial CLND. Methods A retrospective cohort study of 193 patients who underwent CLND for PTC between June 2002 and November 2007 was undertaken. Data gathered included patient demographics, number of lymph nodes excised, lymph node involvement, and incidence of postoperative complications. Results One-hundred and seventy (M/F: 28/142) patients (Grp A) had a CLND as part of their primary surgical procedure while 23 (M/F: 10/13) patients (Grp B) underwent CLND as a secondary procedure (12 therapeutic/11 prophylactic procedures). The mean number of lymph nodes sampled and the % involved in the 2 groups A and B were 9.2 vs 10.2 and 64% vs 61%, respectively. Similarly, the incidence of temporary hypocalcemia (12% vs 9%), permanent hypoparathyroidism (1.8% vs 0%), temporary recurrent laryngeal nerve (RLN) paresis (3% vs 4%), permanent RLN paresis (0.6% vs 0%), and wound infection (0.6% vs 4.3%) was comparable in groups A and B. Conclusion This study demonstrates that there is no additional morbidity when CLND is performed as a secondary procedure for patients with PTC. Secondary CLND should be performed in patients with proven central compartment metastatic disease after previous thyroidectomy and can be offered safely as a prophylactic procedure to patients at high risk for central lymph node metastasis when CLND has not been performed at initial primary operation for PTC.
doi_str_mv 10.1016/j.surg.2009.01.013
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67140543</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0039606009000774</els_id><sourcerecordid>20082104</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-3c4377ec8f31420f8d6a48a1c37f9e60b765649800f0bab0876c590d064fd4e43</originalsourceid><addsrcrecordid>eNqFkkGL1TAQx4Mo7tvVL-BBctFbn5MmTVqRFXmsurDgQT2HNJm6ebZNTVqh396U91DwoDAQMvxmMvn_h5BnDPYMmHx13KclftuXAM0eWA7-gOxYxctCcckekh0AbwoJEi7IZUpHyKBg9WNywRquKslgR8YDjnM0Pe3XYbqnY3BInU8J7ezDSE2ihuZLGJ2JK51isOiWiLQLkU5m8n2_5ef7NQbvqDWjxfia3qacwowZ59DRIcTWOz-vb5-QR53pEz49n1fk6_ubL4ePxd2nD7eHd3eFFQrmglvBlUJbd5yJErraSSNqwyxXXYMSWiUrKZoaoIPWtFAraasGHEjROYGCX5GXp7554h8LplkPPlnM044YlqSlYgIqwf8LZnHrksHWsTyBNoaUInZ6in7In9cM9GaHPurNjq2i0cBybN2fn7sv7YDuT8lZ_wy8OAMmWdN3MQvo02-uZIKXjWoy9-bEYRbtp8eok_WYxXY-Zqu0C_7fc1z_VW57P_r84ndcMR3DEsdsh2Y6lRr0521xtr2BJu-MUoL_AnEwvbc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20082104</pqid></control><display><type>article</type><title>Central lymph node dissection as a secondary procedure for papillary thyroid cancer: Is there added morbidity?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Alvarado, Raul, MD ; Sywak, Mark S., MBBS, FRACS ; Delbridge, Leigh, MD, FACS ; Sidhu, Stan B., PhD, FRACS</creator><creatorcontrib>Alvarado, Raul, MD ; Sywak, Mark S., MBBS, FRACS ; Delbridge, Leigh, MD, FACS ; Sidhu, Stan B., PhD, FRACS</creatorcontrib><description>Background Routine central lymph node dissection (CLND) for papillary thyroid cancer (PTC) at the time of initial thyroidectomy has been advocated with a demonstrated decrease in post-ablation serum thyroglobulin compared to total thyroidectomy alone. Patients now present with central compartment metastatic disease after initial thyroid cancer surgery, or with a diagnosis of PTC after diagnostic lobectomy requiring completion thyroidectomy, and an undissected central compartment. Our aim was to compare the clinical outcomes in patients with PTC who underwent CLND as a secondary event with those having initial CLND. Methods A retrospective cohort study of 193 patients who underwent CLND for PTC between June 2002 and November 2007 was undertaken. Data gathered included patient demographics, number of lymph nodes excised, lymph node involvement, and incidence of postoperative complications. Results One-hundred and seventy (M/F: 28/142) patients (Grp A) had a CLND as part of their primary surgical procedure while 23 (M/F: 10/13) patients (Grp B) underwent CLND as a secondary procedure (12 therapeutic/11 prophylactic procedures). The mean number of lymph nodes sampled and the % involved in the 2 groups A and B were 9.2 vs 10.2 and 64% vs 61%, respectively. Similarly, the incidence of temporary hypocalcemia (12% vs 9%), permanent hypoparathyroidism (1.8% vs 0%), temporary recurrent laryngeal nerve (RLN) paresis (3% vs 4%), permanent RLN paresis (0.6% vs 0%), and wound infection (0.6% vs 4.3%) was comparable in groups A and B. Conclusion This study demonstrates that there is no additional morbidity when CLND is performed as a secondary procedure for patients with PTC. Secondary CLND should be performed in patients with proven central compartment metastatic disease after previous thyroidectomy and can be offered safely as a prophylactic procedure to patients at high risk for central lymph node metastasis when CLND has not been performed at initial primary operation for PTC.</description><identifier>ISSN: 0039-6060</identifier><identifier>EISSN: 1532-7361</identifier><identifier>DOI: 10.1016/j.surg.2009.01.013</identifier><identifier>PMID: 19375610</identifier><identifier>CODEN: SURGAZ</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Biological and medical sciences ; Carcinoma, Papillary - secondary ; Carcinoma, Papillary - surgery ; Cohort Studies ; Endocrinopathies ; Female ; General aspects ; Humans ; Lymph Node Excision - adverse effects ; Male ; Malignant tumors ; Medical sciences ; Reoperation ; Retrospective Studies ; Surgery ; Thyroid Neoplasms - pathology ; Thyroid Neoplasms - surgery ; Thyroid. Thyroid axis (diseases) ; Thyroidectomy - adverse effects ; Treatment Outcome</subject><ispartof>Surgery, 2009-05, Vol.145 (5), p.514-518</ispartof><rights>Mosby, Inc.</rights><rights>2009 Mosby, Inc.</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-3c4377ec8f31420f8d6a48a1c37f9e60b765649800f0bab0876c590d064fd4e43</citedby><cites>FETCH-LOGICAL-c470t-3c4377ec8f31420f8d6a48a1c37f9e60b765649800f0bab0876c590d064fd4e43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0039606009000774$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=21432979$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19375610$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alvarado, Raul, MD</creatorcontrib><creatorcontrib>Sywak, Mark S., MBBS, FRACS</creatorcontrib><creatorcontrib>Delbridge, Leigh, MD, FACS</creatorcontrib><creatorcontrib>Sidhu, Stan B., PhD, FRACS</creatorcontrib><title>Central lymph node dissection as a secondary procedure for papillary thyroid cancer: Is there added morbidity?</title><title>Surgery</title><addtitle>Surgery</addtitle><description>Background Routine central lymph node dissection (CLND) for papillary thyroid cancer (PTC) at the time of initial thyroidectomy has been advocated with a demonstrated decrease in post-ablation serum thyroglobulin compared to total thyroidectomy alone. Patients now present with central compartment metastatic disease after initial thyroid cancer surgery, or with a diagnosis of PTC after diagnostic lobectomy requiring completion thyroidectomy, and an undissected central compartment. Our aim was to compare the clinical outcomes in patients with PTC who underwent CLND as a secondary event with those having initial CLND. Methods A retrospective cohort study of 193 patients who underwent CLND for PTC between June 2002 and November 2007 was undertaken. Data gathered included patient demographics, number of lymph nodes excised, lymph node involvement, and incidence of postoperative complications. Results One-hundred and seventy (M/F: 28/142) patients (Grp A) had a CLND as part of their primary surgical procedure while 23 (M/F: 10/13) patients (Grp B) underwent CLND as a secondary procedure (12 therapeutic/11 prophylactic procedures). The mean number of lymph nodes sampled and the % involved in the 2 groups A and B were 9.2 vs 10.2 and 64% vs 61%, respectively. Similarly, the incidence of temporary hypocalcemia (12% vs 9%), permanent hypoparathyroidism (1.8% vs 0%), temporary recurrent laryngeal nerve (RLN) paresis (3% vs 4%), permanent RLN paresis (0.6% vs 0%), and wound infection (0.6% vs 4.3%) was comparable in groups A and B. Conclusion This study demonstrates that there is no additional morbidity when CLND is performed as a secondary procedure for patients with PTC. Secondary CLND should be performed in patients with proven central compartment metastatic disease after previous thyroidectomy and can be offered safely as a prophylactic procedure to patients at high risk for central lymph node metastasis when CLND has not been performed at initial primary operation for PTC.</description><subject>Biological and medical sciences</subject><subject>Carcinoma, Papillary - secondary</subject><subject>Carcinoma, Papillary - surgery</subject><subject>Cohort Studies</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>General aspects</subject><subject>Humans</subject><subject>Lymph Node Excision - adverse effects</subject><subject>Male</subject><subject>Malignant tumors</subject><subject>Medical sciences</subject><subject>Reoperation</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Thyroid Neoplasms - pathology</subject><subject>Thyroid Neoplasms - surgery</subject><subject>Thyroid. Thyroid axis (diseases)</subject><subject>Thyroidectomy - adverse effects</subject><subject>Treatment Outcome</subject><issn>0039-6060</issn><issn>1532-7361</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkkGL1TAQx4Mo7tvVL-BBctFbn5MmTVqRFXmsurDgQT2HNJm6ebZNTVqh396U91DwoDAQMvxmMvn_h5BnDPYMmHx13KclftuXAM0eWA7-gOxYxctCcckekh0AbwoJEi7IZUpHyKBg9WNywRquKslgR8YDjnM0Pe3XYbqnY3BInU8J7ezDSE2ihuZLGJ2JK51isOiWiLQLkU5m8n2_5ef7NQbvqDWjxfia3qacwowZ59DRIcTWOz-vb5-QR53pEz49n1fk6_ubL4ePxd2nD7eHd3eFFQrmglvBlUJbd5yJErraSSNqwyxXXYMSWiUrKZoaoIPWtFAraasGHEjROYGCX5GXp7554h8LplkPPlnM044YlqSlYgIqwf8LZnHrksHWsTyBNoaUInZ6in7In9cM9GaHPurNjq2i0cBybN2fn7sv7YDuT8lZ_wy8OAMmWdN3MQvo02-uZIKXjWoy9-bEYRbtp8eok_WYxXY-Zqu0C_7fc1z_VW57P_r84ndcMR3DEsdsh2Y6lRr0521xtr2BJu-MUoL_AnEwvbc</recordid><startdate>20090501</startdate><enddate>20090501</enddate><creator>Alvarado, Raul, MD</creator><creator>Sywak, Mark S., MBBS, FRACS</creator><creator>Delbridge, Leigh, MD, FACS</creator><creator>Sidhu, Stan B., PhD, FRACS</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20090501</creationdate><title>Central lymph node dissection as a secondary procedure for papillary thyroid cancer: Is there added morbidity?</title><author>Alvarado, Raul, MD ; Sywak, Mark S., MBBS, FRACS ; Delbridge, Leigh, MD, FACS ; Sidhu, Stan B., PhD, FRACS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-3c4377ec8f31420f8d6a48a1c37f9e60b765649800f0bab0876c590d064fd4e43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Biological and medical sciences</topic><topic>Carcinoma, Papillary - secondary</topic><topic>Carcinoma, Papillary - surgery</topic><topic>Cohort Studies</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>General aspects</topic><topic>Humans</topic><topic>Lymph Node Excision - adverse effects</topic><topic>Male</topic><topic>Malignant tumors</topic><topic>Medical sciences</topic><topic>Reoperation</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Thyroid Neoplasms - pathology</topic><topic>Thyroid Neoplasms - surgery</topic><topic>Thyroid. Thyroid axis (diseases)</topic><topic>Thyroidectomy - adverse effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alvarado, Raul, MD</creatorcontrib><creatorcontrib>Sywak, Mark S., MBBS, FRACS</creatorcontrib><creatorcontrib>Delbridge, Leigh, MD, FACS</creatorcontrib><creatorcontrib>Sidhu, Stan B., PhD, FRACS</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alvarado, Raul, MD</au><au>Sywak, Mark S., MBBS, FRACS</au><au>Delbridge, Leigh, MD, FACS</au><au>Sidhu, Stan B., PhD, FRACS</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Central lymph node dissection as a secondary procedure for papillary thyroid cancer: Is there added morbidity?</atitle><jtitle>Surgery</jtitle><addtitle>Surgery</addtitle><date>2009-05-01</date><risdate>2009</risdate><volume>145</volume><issue>5</issue><spage>514</spage><epage>518</epage><pages>514-518</pages><issn>0039-6060</issn><eissn>1532-7361</eissn><coden>SURGAZ</coden><abstract>Background Routine central lymph node dissection (CLND) for papillary thyroid cancer (PTC) at the time of initial thyroidectomy has been advocated with a demonstrated decrease in post-ablation serum thyroglobulin compared to total thyroidectomy alone. Patients now present with central compartment metastatic disease after initial thyroid cancer surgery, or with a diagnosis of PTC after diagnostic lobectomy requiring completion thyroidectomy, and an undissected central compartment. Our aim was to compare the clinical outcomes in patients with PTC who underwent CLND as a secondary event with those having initial CLND. Methods A retrospective cohort study of 193 patients who underwent CLND for PTC between June 2002 and November 2007 was undertaken. Data gathered included patient demographics, number of lymph nodes excised, lymph node involvement, and incidence of postoperative complications. Results One-hundred and seventy (M/F: 28/142) patients (Grp A) had a CLND as part of their primary surgical procedure while 23 (M/F: 10/13) patients (Grp B) underwent CLND as a secondary procedure (12 therapeutic/11 prophylactic procedures). The mean number of lymph nodes sampled and the % involved in the 2 groups A and B were 9.2 vs 10.2 and 64% vs 61%, respectively. Similarly, the incidence of temporary hypocalcemia (12% vs 9%), permanent hypoparathyroidism (1.8% vs 0%), temporary recurrent laryngeal nerve (RLN) paresis (3% vs 4%), permanent RLN paresis (0.6% vs 0%), and wound infection (0.6% vs 4.3%) was comparable in groups A and B. Conclusion This study demonstrates that there is no additional morbidity when CLND is performed as a secondary procedure for patients with PTC. Secondary CLND should be performed in patients with proven central compartment metastatic disease after previous thyroidectomy and can be offered safely as a prophylactic procedure to patients at high risk for central lymph node metastasis when CLND has not been performed at initial primary operation for PTC.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>19375610</pmid><doi>10.1016/j.surg.2009.01.013</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0039-6060
ispartof Surgery, 2009-05, Vol.145 (5), p.514-518
issn 0039-6060
1532-7361
language eng
recordid cdi_proquest_miscellaneous_67140543
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Biological and medical sciences
Carcinoma, Papillary - secondary
Carcinoma, Papillary - surgery
Cohort Studies
Endocrinopathies
Female
General aspects
Humans
Lymph Node Excision - adverse effects
Male
Malignant tumors
Medical sciences
Reoperation
Retrospective Studies
Surgery
Thyroid Neoplasms - pathology
Thyroid Neoplasms - surgery
Thyroid. Thyroid axis (diseases)
Thyroidectomy - adverse effects
Treatment Outcome
title Central lymph node dissection as a secondary procedure for papillary thyroid cancer: Is there added morbidity?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T14%3A13%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Central%20lymph%20node%20dissection%20as%20a%20secondary%20procedure%20for%20papillary%20thyroid%20cancer:%20Is%20there%20added%20morbidity?&rft.jtitle=Surgery&rft.au=Alvarado,%20Raul,%20MD&rft.date=2009-05-01&rft.volume=145&rft.issue=5&rft.spage=514&rft.epage=518&rft.pages=514-518&rft.issn=0039-6060&rft.eissn=1532-7361&rft.coden=SURGAZ&rft_id=info:doi/10.1016/j.surg.2009.01.013&rft_dat=%3Cproquest_cross%3E20082104%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20082104&rft_id=info:pmid/19375610&rft_els_id=1_s2_0_S0039606009000774&rfr_iscdi=true